Chuckles of the Day

Husband and Wife

A husband and wife are getting ready for bed.

The wife is standing in front of a full length mirror taking a hard look at herself.

“You know love” she says, “I look in the mirror and I see an old woman. My face is all wrinkled, my boobs are barely above my waist, my butt is hanging out a mile. I’ve got fat legs and my arms are all flabby.”

She turns to her husband and says, “Tell me something positive to make me feel better about myself”.

He thinks about it for a bit and then says,

“Well . . . . . . there’s nothing wrong with your eyesight”.

* * * * * * *

A husband and wife were having a 60th birthday party and a 40th anniversary party.

While the party was in full swing, a fairy showed up. He said that he was there to grant each of them a wish. He turned to the wife and asked what she would like to have.

She said, ” I have always thought that a cruise around the world for two would be fantastic.”

The fairy picked up his wand and “Presto” she held in her hand two tickets for an around-the-world cruise.

The fairy then turned to the husband and asked what he would like to have.

He responded, ” I have always thought it would be nice to have a wife 30 years younger than me.”

The fairy picked up his wand and “Presto” the husband turned 90.

Targeted Radiotherapy Might Help Men Battling Advanced Prostate Cancer

Cara Murez wrote . . . . . . . . .

Patients with advanced prostate cancers may have newfound hope: Researchers identified a new potential treatment for men with metastatic castration-resistant prostate cancer, which has no cure.

Metastatic castration-resistant prostate cancer means the disease continues to spread despite therapies that deplete male hormones (androgens) such as testosterone, which are thought to “feed” tumors.

When added to standard care, this novel targeted radiotherapy improved survival for these cancer patients, researchers report.

The study “offers the treatment possibility where there was really very little for the most advanced patient, but it opens a doorway for exploring the benefits of this drug in multiple earlier patient populations,” said Dr. Michael Morris, head of the Prostate Cancer Section at Memorial Sloan Kettering Cancer Center in New York City.

In about 80% of prostate cancers, there is a protein on the surface of the cancer cell that is called prostate-specific membrane antigen (PSMA). It is also distributed on prostate cancer that has spread to the bone, lymph nodes or soft tissues. Yet, PSMA is not on normal tissues, so it was a good target for both diagnostics and therapeutics, Morris explained.

The new drug has two components, a targeting molecule and a payload delivers radiation. It is given intravenously.

“Each of the molecules of drug is seeking to bind with the cells containing PSMA, which generally are the prostate cancer cell. As the drug binds to it, the cell brings the drug into the interior of the cell. The radiation, which is attached to the drug, it’s the payload of the drug, is also brought into the interior of the cell. And there, it irradiates the cell and kills it as well as the cells that are neighboring to it,” Morris said.

To be a part of the trial, the patients had to have disease that had progressed through testosterone-lowering therapy, which has been the standard for decades, Morris said. They also had to have progressed through another class of drugs known as androgen-receptor pathway inhibitors and through chemotherapy.

“What happens when you go on to treatment with prostate cancer is that if you respond, you stay on that therapy or stay on that regimen until either side effects preclude continuing the therapy or it no longer works because the disease has become resistant to it,” Morris explained.

The trial included 831 participants. Patients were randomized two-to-one to receive the new treatment, called lutetium-labeled PSMA-617, plus standard care or just standard care between June 2018 and October 2019.

The new treatment increased overall median survival to 15.3 months versus 11.3 months for these patients who had very advanced disease. It also increased a measure called radiographic progression-free survival, which reflects disease control while on the drug, from a median of 3.4 months to 8.7 months.

The study is being presented online at the American Society of Clinical Oncology annual meeting, which will be held June 4-8. Findings presented at medical meetings are considered preliminary until published in a peer-reviewed journal. Drug maker Novartis funded the study and plans to submit the data to regulatory authorities for review and potential approval.

Prostate cancer is both the most common cancer in American men and the second leading cause of cancer-related death. The study’s positive results mean that patients who have very advanced disease might have a new treatment option.

“It also means that, usually in prostate cancer as well as other diseases, what you develop and discover as a new therapy for the most advanced patients usually benefits earlier patients and frequently we’ll see those benefits amplified in less sick patients who have less-resistant disease,” Morris said.

Current studies are now looking at the therapy for patients who have earlier disease who have not yet received chemotherapy, as well as those who are just beginning treatments for prostate cancer.

Dr. Ash Tewari, system chair in the Milton and Carroll Petrie Department of Urology at Mount Sinai Health System in New York City, said the study offers a lot of promise for patients, giving those with advanced prostate cancer new hope. It also has a reasonable side effect profile, said Tewari, who was not involved in the study.

“Androgen deprivation is the mainstay of therapy of advanced prostate cancer, but the cure rate is low and patients eventually become castrate-resistant,” Tewari said. “There is a need to more closely tailor therapies to individual patient profiles.”

Noting the median results for overall survival that the study found, Tewari said that extra four months of life can be very meaningful for someone who lives to see an important family milestone, such as a grandchild’s wedding.

“This is a good example of when a well-conducted clinical trial backed by scientific data can make an impact in patient’s life. And we should always be curiously, cautiously looking at these options,” he said.

Source: HealthDay

High Caffeine Consumption May be Associated with Increased Risk of Glaucoma

Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure according to an international, multi-center study. The research led by the Icahn School of Medicine at Mount Sinai is the first to demonstrate a dietary – genetic interaction in glaucoma. The study results published in the journal Ophthalmology may suggest patients with a strong family history of glaucoma should cut down on caffeine intake.

The study is important because glaucoma is the leading cause of blindness in the United States. It looks at the impact of caffeine intake on glaucoma, and intraocular pressure (IOP) which is pressure inside the eye. Elevated IOP is an integral risk factor for glaucoma, although other factors do contribute to this condition. With glaucoma, patients typically experience few or no symptoms until the disease progresses and they have vision loss.

“We previously published work suggesting that high caffeine intake increased the risk of the high-tension open angle glaucoma among people with a family history of disease. In this study we show that an adverse relation between high caffeine intake and glaucoma was evident only among those with the highest genetic risk score for elevated eye pressure,” says lead/corresponding author Louis R. Pasquale, MD, FARVO, Deputy Chair for Ophthalmology Research for the Mount Sinai Health System.

A team of researchers used the UK Biobank, a large-scale population-based biomedical database supported by various health and governmental agencies. They analyzed records of more than 120,000 participants between 2006 and 2010. Participants were between 39 and 73 years old and provided their health records along with DNA samples, collected to generate data. They answered repeated dietary questionnaires focusing on how many caffeinated beverages they drink daily, how much caffeine-containing food they eat, the specific types, and portion size. They also answered questions about their vision, including specifics on if they have glaucoma or a family history of glaucoma. Three years into the study later they had their IOP checked and eye measurements.

Researchers first looked at the relationship looked between caffeine intake, IOP and self-reported glaucoma by running multivariable analyses. Then they assessed if accounting for genetic data modified these relationships. They assigned each subject an IOP genetic risk score and performed interaction analyses.

The investigators found high caffeine intake was not associated with increased risk for higher IOP or glaucoma overall; however, among participants with the strongest genetic predisposition to elevated IOP – in the top 25 percentile – greater caffeine consumption was associated with higher IOP and higher glaucoma prevalence. More specifically, those who consumed the highest amount of daily caffeine– more than 480 milligrams which is roughly four cups of coffee – had a 0.35 mmHg higher IOP. Additionally, those in the highest genetic risk score category who consumed more than 321 milligrams of daily caffeine – roughly three cups of coffee – had a 3.9-fold higher glaucoma prevalence when compared to those who drink no or minimal caffeine and in lowest genetic risk score group.

“Glaucoma patients often ask if they can help to protect their sight through lifestyle changes, however this has been a relatively understudied area until now. This study suggested that those with the highest genetic risk for glaucoma may benefit from moderating their caffeine intake. It should be noted that the link between caffeine and glaucoma risk was only seen with a large amount of caffeine and in those with the highest genetic risk,” says co-author Anthony Khawaja, MD, PhD, Associate Professor of Ophthalmology University College London (UCL) Institute of Ophthalmology and ophthalmic surgeon at Moorfields Eye Hospital. “The UK Biobank study is helping us to learn more than ever before about how our genes affect our glaucoma risk and the role that our behaviors and environment could play. We look forward to continuing to expand our knowledge in this area.”

Source: Icahn School of Medicine at Mount Sinai

Blackened Chicken and Creole Lentils


8 skinless chicken breasts or thighs
1/4 cup Cajun spice mix
2 Tbsp canola oil
2 Tbsp canola oil
1 cup thinly sliced onion
2 cups thinly sliced mushrooms
1 Tbsp tomato paste
2 tsp Cajun spice mix
1 cups chicken stock
2 cups cooked or canned green lentils, drained and rinsed
1 Tbsp unsalted butter
1 Tbsp lemon juice
3 Tbsp chopped parsley
salt and ground black pepper, to taste

Cajun Spice Mix

4 tsp dried oregano
4 tsp dried thyme
4 tsp garlic powder
2 tsp onion powder
2 tsp ground black pepper
2 tsp ground white pepper
2 tsp ground paprika
1 tsp kosher or coarse salt
1/2 tsp ground cayenne pepper


  1. Preheat oven to 350 ⁰F (180 ⁰C).
  2. Sprinkle chicken evenly on both sides with Cajun spice mix.
  3. Add canola oil in a large ovenproof sauté pan, over medium high heat and sear chicken on each side until spices turn dark but are not burnt.
  4. Finish chicken in the oven. Cook until chicken reaches an internal temperature of 165 ⁰F (74 ⁰C).
  5. Prepare the lentils. In a large saucepan, heat canola oil. Sauté onions until golden. Add mushrooms and cook until golden as well, then add tomato paste with spice mix. Cook for 3 minutes.
  6. Mix in stock, being sure to scrape the tasty bits off the pan with your wooden spoon. Add lentils and simmer for 5-10 minutes or until excess liquid is absorbed.
  7. Add butter, lemon juice, and parsley. Season with salt and pepper. Serve immediately with blackened chicken.

Makes 8 servings.

Source: Dietitians of Canada

Today’s Comic